


# Autism Spectrum Disorder Part III: Genetics and Autism



#### No conflicts of interest to declare

#### Funding sources:














### Learning objectives

- Discuss the role of genetic and environmental factors that contribute to ASD
- Identify the wide range of genetic variation that is involved in ASD including gene-gene and gene-environment interactions
- Review the current status and key findings of genetics research in ASD


## Autism Spectrum Disorder (ASD) is a developmental neurological impairment



- CDC estimates incidence of 1 in 60 (1.7%)
  - More common in males (2:1 to 4:1)
- Individuals with ASD have fewer children Power et al. 2013


#### Genes vs. "The Environment"

- Trait: A characteristic of individuals in a population
  - E.g. milk production in cows
  - Height in humans
  - Sociability in humans
  - Autism spectrum disorder diagnosis



#### Genes vs. "The Environment"


- Trait: A characteristic of individuals in a population
  - E.g. milk production in cows
  - Height in humans
  - Sociability in humans
  - Autism spectrum disorder diagnosis



#### Genes vs. "The Environment"

- Trait: A characteristic of individuals in a population
  - E.g. milk production in cows
  - Height in humans
  - Sociability in humans
  - Autism spectrum disorder diagnosis

2% diagnosed With ASD




- Genes: The variance in a trait explained by heritable factors
- Environment: The variance in a trait explained by everything else
  - "Unaccounted" would be a better phrase
  - Environmental factors are one contributor to this term

### What are researchers trying to achieve?


Genetics




Environmental factors




### Genetics and heritability analyses assess the flow of information in biological systems




### Genotypes are amplified to produce observable phenotypes



# Genotypes are amplified to produce observable phenotypes




## Genotypes are amplified to produce observable phenotypes



Sanders SJ, Curr Opin Genet Dev, 2015

### Genotypes are amplified to produce observable phenotypes




this makes it easier to establish causality


Sanders SJ, Curr Opin Genet Dev, 2015

## Twin studies compare identical (monozygotic) to non-identical (dizygotic) twins

#### Twin study




### Twin study: Combining data across 7 twin studies



Tick et al. Journal of Child Psychology and Psychiatry 2016


### Twin study: Combining data across 7 twin studies




Tick et al. Journal of Child Psychology and Psychiatry 2016

## Family/sibling studies compare relatives (e.g. siblings) to the general population

#### Family study



## Analysis of heritability across ~130 complex human disorders; ASD is the most heritable



## Neuropsychiatric disorders, like ASD, are frequently genetic

Disorder	Clinical utility	Heritability
ASD	Parental counseling	70 - 95%
Schizophrenia	None at present	60 - 90%
Alzheimer's	APOE4 testing?	60 - 80%
Height	Mid-parental height used to estimate expectation	55 - 81%
Multiple Sclerosis	None at present	64%
Migraine	Commonly assessed in the evaluation of headaches	53%
IQ	None at present	50%
Personality	None at present	50%
Breast cancer	Family history guides genetic testing and counseling	25 - 56%
Coronary Heart Disease	Used to inform models of cardiac risk	49%
Type 2 Diabetes	None at present	26%

Source: SNPedia

### What are we trying to achieve?

Genetics – strong contributor, causality can be established; 20,000 genes




Environmental factors – weaker contributor; causality is hard to establish;
100,000s of factors to assess



#### Environmental factors associated with ASD


- Maternal valproate use for epilepsy during pregnancy
  - 2-fold increase in risk Christensen et al. JAMA 2013
  - Does epilepsy carry genetic risk for ASD, or valproate carry environmental risk?
    - 1,623 mothers with epilepsy (22 had children with ASD, 1.4%)
    - 388 mothers on valproate (12 had children with ASD, 3.1%)
    - But was there an additional reason the mothers were on valproate vs. other treatments?
  - Causality is hard to establish
- Many other factors considered, but few thoroughly assessed:
  - Congenital infection, pollutants, pesticides, heavy metals
- Very hard to "guess" what to study without knowing the biology

## The prevalence of ASD has risen over the last few decades




#### Comparison of Growth Areas and Emissions, 1980-2015





## There are many explanations for rising prevalence; simply looking for "new" factors is a risky strategy

- Changing diagnostic methods
- Replacing other diagnoses
  - Developmental delay
  - · Intellectual disability
- Increased surveillance
- Rising parental age
- New ways to find a partner
- Environmental factors




Sources: Organic Trade Association, 2011 Organic Industry Survey, U.S. Department of Education, Office of Special Education Programs, Data Analysis System (DANS), OMB# 1820-0043: "Children with Disabilities Receiving Special Education Under Part B of the Individuals with Disabilities Education Act

#### Genetic factors associated with ASD

- Several genetic syndromes have ASD as a feature
  - Fragile X, Rett's, TSC1, TSC2, NF1, NF2, PTEN, CACNA1C

### Example of a family with neurofibromatosis (NF1) and autosomal dominant inheritance




#### Genetic factors associated with ASD

- Several genetic syndromes have ASD as a feature
  - Fragile X, Rett's, TSC1, TSC2, NF1, NF2, PTEN, CACNA1C
- Using exome sequencing, ASD-associated de novo loss of function mutations are found in ~7% of children with ASD (>10-fold increase in risk)
  - Sanders et al. Nature 2012, replicated in Iossifov et al. Neuron 2012, De Rubeis et al. Nature 2014, Iossifov et al. Nature 2014, Sanders et al. Neuron 2015, and many others

## Large cohorts, new technologies, and new statistical approaches have revolutionized genetics

~2,500 ASD families in Simons Simplex Collection





Microarray






Exome sequencing







# The human genome has 3.2 billion base pairs and 3.3 million variants




# The human genome has 3.2 billion base pairs and 3.3 million variants




### The human genome has 3.2 billion base pairs and 3.3 million variants




## Rarer variants have greater potential to transmit ASD risk due to natural selection




# Missense variants alter one copy of a protein, LoFs disrupt one copy of a protein




# An excess of *de novo* protein truncating variants in ASD cases shows they contribute to ASD risk





Sanders et al, Neuron, 2015


# An excess of *de novo* protein truncating variants in ASD cases shows they contribute to ASD risk





Sanders et al, Neuron, 2015

# An excess of *de novo* protein truncating variants in ASD cases shows they contribute to ASD risk






#### Genetic factors associated with ASD


- Several genetic syndromes have ASD as a feature
  - Fragile X, Rett's, TSC1, TSC2, NF1, NF2, PTEN, CACNA1C
- Using exome sequencing, ASD-associated de novo loss of function mutations are found in ~7% of children with ASD (>10-fold increase in risk)
  - Sanders et al. Nature 2012, replicated in Iossifov et al. Neuron 2012, De Rubeis et al. Nature 2014, Iossifov et al. Nature 2014, Sanders et al. Neuron 2015, and many others
- Using gene microarrays, ASD-associated de novo CNVs are found in ~3% of children with ASD (>10-fold increase in risk)
  - Sebat et al. Science 2007, replicated in Pinto et al. Nature 2010, Sanders et al. Neuron 2011, Pinto et al. AJHG 2014, Sanders et al. Neuron 2015 (over 4,000 cases), and many others

Missense variants **alter** one copy of a protein, LoFs **disrupt** one copy of a protein, copy number variants (CNVs) **disrupt** one copy of multiple proteins




#### Individuals with a diagnosis of ASD have more *de novo* CNVs than unaffected controls


1,991 ASD cases and 1,991 unaffected sibling controls



Sanders et al. Neuron 2015


#### ASD is a frequently a combination of *de novo*, rare, and common variants






Nav1.2 structure from AJ Campbell, Broad

# To distinguish risk mutations from neutral mutations, we identify genes with clusters of mutations



Sanders et al. Neuron 2015

# To distinguish risk mutations from neutral mutations, we identify genes with clusters of mutations



Sanders et al. Neuron 2015

# Assessment of ~8,000 ASD cases has identified 65 ASD risk genes: a constellation of cryptic syndromes




Table 4. Integrating Small De Novo Deletions in TADA Identified 65 ASD Genes				
dnLoF Count	FDR ≤ 0.01	$0.01 < FDR \le 0.05$	0.05 < FDR ≤ 0.1	
≥2	ADNP, ANK2, <b>ARID1B</b> , ASH1L, <b>CHD2</b> , CHD8, CUL3, DSCAM, DYRK1A, GRIN2B, KATNAL2, KDM5B, <b>KMT2C</b> , NCKAP1, POGZ, SCN2A, SUV420H1, <b>SYNGAP1</b> , TBR1, <b>TCF7L2</b> , <b>TNRC6B</b> , WAC	BCL11A, FOXP1, GIGYF1, ILF2, KDM6B, PHF2, RANBP17, SPAST, WDFY3	DIP2A, KMT2E	
1	NRXN1, PTEN, SETD5, SHANK2, SHANK3, TRIP12	DNMT3A, GABRB3, <b>KAT2B</b> , MFRP, MYT1L, P2RX5	AKAP9, APH1A, CTTNBP2, ERBB2IP, ETFB, INTS6, IRF2BPL, <b>MBD5</b> , NAA15, NINL, OR52M1, PTK7, TRIO, USP45	
0	-	MIB1, SLC6A1, ZNF559	ACHE, CAPN12, NLGN3	
Genes with a small de novo deletion are in bold. FDR, false discovery rate.			Sanders et al. Neuron, 2015	

# Assessment of ~8,000 ASD cases has identified 65 ASD risk genes: a constellation of cryptic syndromes




Table 4. Integrating Small De Novo Deletions in TADA Identified 65 ASD Genes			
dnLoF Count	FDR ≤ 0.01	$0.01 < FDR \le 0.05$	0.05 < FDR ≤ 0.1
≥2	ADNP, ANK2, ARID1B, ASH1L, CHD2, CHD8, CUL3, DSCAM, DYRK1A, GRIN2B, KATNAL2_KDM5B, KMT2C, NCKAP1, POG. SCN2A, UV420H1, SYNGAP1, TBR1, TCF7L2, TNRC6B, WAC	BCL11A, FOXP1, GIGYF1, ILF2, KDM6B, PHF2, RANBP17, SPAST, WDFY3	DIP2A, KMT2E
1	NRXN1, PTEN, SETD5, SHANK2, SHANK3, TRIP12	DNMT3A, GABRB3, <b>KAT2B</b> , MFRP, MYT1L, P2RX5	AKAP9, APH1A, CTTNBP2, ERBB2IP, ETFB, INTS6, IRF2BPL, <b>MBD5</b> , NAA15, NINL, OR52M1, PTK7, TRIO, USP45
0	-	MIB1, SLC6A1, ZNF559	ACHE, CAPN12, <b>NLGN3</b>
Genes with a small de novo deletion are in bold. FDR, false discovery rate.			Sanders et al. Neuron, 2015

#### Trends in Neurosciences

Volume 41 Number 7 July 2018 ISSN 0166-2236



#### Review

#### Progress in Understanding and Treating SCN2A-Mediated Disorders


Stephan J. Sanders, <sup>1,\*</sup> Arthur J. Campbell, <sup>2</sup> Jeffrey R. Cottrell, <sup>2</sup> Rikke S. Moller, <sup>3</sup> Florence F. Wagner, <sup>2</sup> Angie L. Auldridge, <sup>4</sup> Raphael A. Bernier, <sup>5</sup> William A. Catterall, <sup>6</sup> Wendy K. Chung, <sup>7,8</sup> James R. Empfield, <sup>9</sup> Alfred L. George Jr, <sup>10</sup> Joerg F. Hipp, <sup>11</sup> Omar Khwaja, <sup>11</sup> Evangelos Kiskinis, <sup>12,13</sup> Dennis Lal, <sup>2</sup> Dheeraj Malhotra, <sup>11</sup> John J. Millichap, <sup>12,14,15</sup> Thomas S. Otis, <sup>16</sup> Steven Petrou, <sup>17</sup> Geoffrey Pitt, <sup>18</sup> Leah F. Schust, <sup>4</sup> Cora M. Taylor, <sup>19</sup> Jennifer Tjernagel, <sup>7</sup> John E. Spiro, <sup>7</sup> and Kevin J. Bender<sup>20,\*</sup>





SCN2A in Neurodevelopmental Disorders





















#### Along with ASD, genetic variants in *SCN2A* are associated with three disorders


	Disorder name	Infantile Seizures (<12mths)	Ongoing seizures (>2yrs)	Developmental delay
BIS	Benign (familial) infantile seizures	Υ	N	N
IEE	Infantile epileptic encephalopathy	Υ	Υ	Υ
ASD/ID	Autism Spectrum Disorder/ID	N	~25%	Υ


### Along with ASD, genetic variants in *SCN2A* are associated with three disorders

	Disorder name	Infantile Seizures (<12mths)	Ongoing seizures (>2yrs)	Developmental delay
BIS	Benign (familial) infantile seizures	Υ	N	N
IEE	Infantile epileptic encephalopathy	Υ	Υ	Υ
ASD/ID	Autism Spectrum Disorder/ID	N	~25%	Υ




# Loss of function in one copy of *SCN2A* makes excitatory neurons less excitable during development








#### Understanding the role of one gene provides some insight into when and how ASD occurs

- A 50% reduction in SCN2A function leads to ASD
- This implicates excitatory neurons in ASD
- It suggests that a reduction in neuron excitability may be involved
- It suggests that the "cause" of ASD occurs before 1yr of age









# Assessment of ~8,000 ASD cases has identified 65 ASD risk genes: a constellation of cryptic syndromes






Table 4. Integrating Small De Novo Deletions in TADA Identified 65 ASD Genes				
dnLoF Count	FDR ≤ 0.01	$0.01 < FDR \le 0.05$	0.05 < FDR ≤ 0.1	
≥2	ADNP, ANK2, <b>ARID1B</b> , ASH1L, <b>CHD2</b> , CHD8, CUL3, DSCAM, DYRK1A, GRIN2B, KATNAL2, KDM5B, <b>KMT2C</b> , NCKAP1, POGZ, SCN2A, SUV420H1, <b>SYNGAP1</b> , TBR1, <b>TCF7L2</b> , <b>TNRC6B</b> , WAC	BCL11A, FOXP1, GIGYF1, ILF2, KDM6B, PHF2, RANBP17, SPAST, WDFY3	DIP2A, KMT2E	
1	NRXN1, PTEN, SETD5, SHANK2, SHANK3, TRIP12	DNMT3A, GABRB3, <b>KAT2B</b> , MFRP, MYT1L, P2RX5	AKAP9, APH1A, CTTNBP2, ERBB2IP, ETFB, INTS6, IRF2BPL, <b>MBD5</b> , NAA15, NINL, OR52M1, PTK7, TRIO, USP45	
0	-	MIB1, SLC6A1, ZNF559	ACHE, CAPN12, NLGN3	
Genes with a small de novo deletion are in bold. FDR, false discovery rate.			Sanders et al. Neuron, 2015	

# The 65 ASD risk genes converge on chromatin and synaptic networks



Sanders et al. Neuron, 2015

#### By considering the ASD-associated genes alongside other datasets, we can start to understand the 20,000ft view









**ENCODE: Encyclopedia of DNA Elements** 

Sanders SJ Curr Opin Genet Dev 2015

#### Considering multiple genes in together also provides insight into when and how ASD occurs

- Two main groups of ASD-associated genes involved in:
  - Gene expression regulation
  - Neuronal communication
- Implicates prefrontal cortex in mid-fetal development
- Enriched for excitatory neurons and striatal neurons

#### Summary

- There is strong evidence that genetic factors play a role in ASD
  - Twin studies
  - Family studies
  - Syndromes
  - De novo mutations
- De novo mutations have identified ~65 genes associated with ASD
- These genes are providing insight into ASD etiology
  - Gene expression and neuronal communication
  - Early development (<1yr)</li>
  - Excitatory neurons in the cortex
- Environmental factors are likely to be involved
  - Harder to search for than genetic factors

#### Useful information sources of ASD information

- Spectrum: <a href="https://www.spectrumnews.org">https://www.spectrumnews.org</a>
- Autism Science Foundation: <a href="https://autismsciencefoundation.org">https://autismsciencefoundation.org</a>
- Autism Society: <a href="http://www.autism-societv.org">http://www.autism-societv.org</a>
- International Society for Autism Research: <a href="https://www.autism-insar.org">https://www.autism-insar.org</a>